GlaxoSmithKline’s (GSK) “Buy” Rating Reiterated at UBS Group
GlaxoSmithKline (NYSE:GSK)‘s stock had its “buy” rating restated by equities research analysts at UBS Group in a research note issued to investors on Monday, www.boersen-zeitung.de reports.
GSK has been the subject of several other reports. Cowen set a $38.00 target price on shares of GlaxoSmithKline and gave the company a “hold” rating in a research note on Monday, December 11th. ValuEngine cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Argus decreased their target price on shares of GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a research note on Thursday, November 30th. Finally, Bank of America cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $38.57.
GlaxoSmithKline (GSK) traded up $0.66 on Monday, hitting $37.50. 4,999,657 shares of the company traded hands, compared to its average volume of 5,400,000. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline has a 1 year low of $34.52 and a 1 year high of $44.53. The firm has a market cap of $92,080.00, a PE ratio of 28.85, a P/E/G ratio of 2.15 and a beta of 0.97.
In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in GSK. Principal Financial Group Inc. purchased a new stake in shares of GlaxoSmithKline during the second quarter worth $602,000. King Luther Capital Management Corp grew its holdings in shares of GlaxoSmithKline by 1.0% during the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after buying an additional 55 shares in the last quarter. Bahl & Gaynor Inc. grew its holdings in shares of GlaxoSmithKline by 0.9% during the second quarter. Bahl & Gaynor Inc. now owns 17,481 shares of the pharmaceutical company’s stock worth $673,000 after buying an additional 150 shares in the last quarter. Stevens Capital Management LP grew its holdings in shares of GlaxoSmithKline by 17.1% during the second quarter. Stevens Capital Management LP now owns 40,674 shares of the pharmaceutical company’s stock worth $1,754,000 after buying an additional 5,933 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of GlaxoSmithKline by 0.3% during the second quarter. PNC Financial Services Group Inc. now owns 1,133,608 shares of the pharmaceutical company’s stock worth $48,881,000 after buying an additional 3,698 shares in the last quarter. 9.80% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline’s (GSK) “Buy” Rating Reiterated at UBS Group” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/15/glaxosmithklines-gsk-buy-rating-reiterated-at-ubs-group.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.